Shockwaves and extracellular vesicles in tissue repair · Lab study · 2026
Could shockwave work by changing the tiny particles cells release?
Cells send signals to each other in tiny particles called extracellular vesicles. This review of cell, mouse and rat studies found that after shockwave, these particles carried signals linked to blood-vessel growth and healing; in some studies their number rose, in others not.
Explores how shockwave works- core studies in cells, mice and rats
- 6
- of 5 tabled studies found more particles released
- 2
- year published
- 2026
Good to know: The authors present this as a hypothesis.
Zhang S, Gao Y, Zhou J, et al. Frontiers in Cell and Developmental Biology, 2026 · Read the paper ↗
The treatment
- Exposures in the core studies
- As printed in Table 3: endothelial colony-forming cells 0.09 mJ/mm², 500 shots; H9c2 cells 0.12 mJ/mm², 500 shots; adipose-derived stromal cells 0.1 mJ/mm², 800 impulses; rat tibial osteotomy 3 bar, 300 impulses, 5 Hz (a radial device, per the cited title); the mouse heart study’s parameters are not given in the table.
- How vesicles reached the tissue
- Two routes: shock wave applied in the living animal (rat tibial osteotomy, with circulating vesicles studied), or donor cells treated in culture and their vesicles injected into the mouse heart or instilled into the rat bladder in a magnetic, temperature-sensitive chitosan hydrogel.
Who took part
Human and animal cells grown in the lab, mice after a heart attack, rats with skin wounds and a cut shin bone, and rats with diabetes-related bladder problems.
Side effects
The review does not report side effects.
All the numbers and the full appraisal
What the full paper reports.
Cell and animal work only: human umbilical vein endothelial cells, endothelial colony-forming cells, H9c2 cardiomyoblast-like cells, bone-marrow mesenchymal stem cells and adipose-derived stromal cells; a mouse myocardial infarction model, a rat skin-wound model with tibial osteotomy and a rat model of diabetic bladder dysfunction. The human studies cited concern circulating microRNAs in heart and vascular disease, not shockwave treatment.
Vesicle release after shock wave1 reported outcome
Vesicle release after shock wave
Vesicle release after shock wave Narrative finding
Table 3 reports vesicle yield as an increase with high variance (endothelial cells), a significant increase (plasma and bone-marrow stem cells), no change (endothelial colony-forming cells), no increase (H9c2 cells) and not measured (adipose-derived cells). In endothelial cells, release did not rise immediately but rose at 1 h and stayed higher at 4 h, with more multivesicular bodies and nSMase2; in stem cells, particle counts rose with CD63, TSG101 and Rab27, and ATP hydrolase, a P2X7R inhibitor and a p38 MAPK inhibitor each blunted the rise.
Analysis details and source
Two of four studies that measured yield found no increase, which tempers the abstract’s statement that shock wave may promote vesicle secretion. The authors add that the markers do not prove the vesicles are exosomes and that their multistage release model combines different cell systems.
Changed microRNA and protein cargo1 reported outcome
Changed microRNA and protein cargo
Changed microRNA and protein cargo Narrative finding
Vesicles from treated endothelial cells were enriched in 31 microRNAs; PCR confirmed miR-7i, miR-19a and miR-19b, not miR-301b, and miR-19a-3p promoted endothelial tube formation, while blocking it reduced angiogenic responses in a mouse hindlimb-ischemia model. Other studies reported 18 (8 up, 10 down) and 39 (20 up, 19 down) differentially expressed microRNAs, pointing to miR-140-3p acting on PTEN/PI3K/AKT and miR-98-5p acting on FOXN3. Proteomics of rat vesicles identified Lcp1, Thbs1 and Hspd1, and shock-wave-primed adipose-derived cells raised GATA4, VEGF and NGF.
Analysis details and source
Laboratory findings. The review notes that another study found miR-19a-3p in cardiomyocyte-derived vesicles inhibited angiogenesis, so a uniformly beneficial effect of this cargo is not established.
Distant skin wounds in rats1 reported outcome
Distant skin wounds in rats
Distant skin wounds in rats Narrative finding
In rats with a full-thickness dorsal foot wound, shock wave at a proximal tibial ring osteotomy improved healing of both the same-side and the opposite-side wound compared with osteotomy alone. Circulating vesicles increased, blocking vesicle release with GW4869 weakened the healing effect, isolated vesicles accumulated in the wound, and giving these vesicles also promoted repair; engineered Thbs1-enriched vesicles sped wound closure and shifted wound macrophages toward the M2 type.
Analysis details and source
Animal model. The authors note that GW4869 is not fully specific, plasma vesicles have mixed origins, and an acute surgical wound does not reproduce chronic diabetic, infected or ischemic wounds.
Heart models in mice and cells1 reported outcome
Heart models in mice and cells
Heart models in mice and cells Narrative finding
Vesicles from shock-wave-treated endothelial cells, injected near the infarct after coronary ligation in mice, were followed by better-preserved left-ventricular function, less fibrosis and more angiogenesis-related features. In cell models of oxygen deprivation and reoxygenation, vesicles from treated cells reduced oxidative stress, apoptosis and injury and enhanced endothelial proliferation and tube formation.
Analysis details and source
The authors stress that these models test vesicles prepared outside the body as a product; they do not show that cardiac shockwave therapy works through vesicles released in the heart.
Diabetic bladder dysfunction in rats1 reported outcome
Diabetic bladder dysfunction in rats
Diabetic bladder dysfunction in rats Narrative finding
In rats with diabetic bladder dysfunction (streptozotocin plus high-fat diet), vesicles from shock-wave-primed adipose-derived cells, instilled in a magnetic chitosan hydrogel held by an external magnet, shortened the prolonged voiding interval, restored maximal voiding pressure and increased detrusor capillary density and S100-positive nerve fibres. In culture, these vesicles increased endothelial tube formation and neurite length.
Analysis details and source
Tests an engineered vesicle product combined with a delivery material, not a direct shock-wave treatment of the bladder; vesicle yield was not measured.
Human data cited1 reported outcome
Human data cited
Human data cited Narrative finding
The human studies cited link circulating miR-19a-3p, miR-140-3p and miR-98-5p with heart attack, coronary disease, carotid stenosis or cardiovascular risk. The review states that these associations do not establish a role for vesicle microRNAs in the effects of shockwave therapy in patients, and that the direction of change for miR-98-5p differs between studies.
Analysis details and source
No study of shockwave and vesicles in people is included.
How treatment was delivered
As printed in Table 3: endothelial colony-forming cells 0.09 mJ/mm², 500 shots; H9c2 cells 0.12 mJ/mm², 500 shots; adipose-derived stromal cells 0.1 mJ/mm², 800 impulses; rat tibial osteotomy 3 bar, 300 impulses, 5 Hz (a radial device, per the cited title); the mouse heart study’s parameters are not given in the table.
Two routes: shock wave applied in the living animal (rat tibial osteotomy, with circulating vesicles studied), or donor cells treated in culture and their vesicles injected into the mouse heart or instilled into the rat bladder in a magnetic, temperature-sensitive chitosan hydrogel.
The review gives no adverse-event data from its core studies, all of which were preclinical. The review notes that excessive mechanical load can injure cells, damage microvessels or worsen inflammation, that vesicle increases must be separated from membrane injury and release of apoptotic debris, and it cites raised inflammatory markers in brain-derived vesicles of military personnel exposed to repeated low-level blasts as a reason to define a safe treatment window. Funding: Liaoning “Xingliao Talent Plan” and Dalian Association of Science and Technology; no conflicts declared and no device-maker ties stated.
Author-reported: evidence comes mainly from in vitro studies, small animals and proof-of-concept experiments; shock-wave parameters, donor cells, isolation methods and sampling times differ; the release model is a working model, not a validated linear pathway; and the heart and bladder models test enhanced vesicle products rather than in situ release.
Extractor interpretation: a small core set (6 studies from 105 records) without a formal risk-of-bias tool; Table 3 lists five of the six included studies; results on vesicle yield are split; and three of the five tabulated studies were published in 2025–2026.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: evidence comes mainly from in vitro studies, small animals and proof-of-concept experiments; shock-wave parameters, donor cells, isolation methods and sampling times differ; the release model is a working model, not a validated linear pathway; and the heart and bladder models test enhanced vesicle products rather than in situ release.
- Extractor interpretation: a small core set (6 studies from 105 records) without a formal risk-of-bias tool; Table 3 lists five of the six included studies; results on vesicle yield are split; and three of the five tabulated studies were published in 2025–2026.
Source-linked critical reading
Narrative review of laboratory and animal studies
Experiments in cells, mice and rats suggest that shockwaves may change the tiny particles (extracellular vesicles) that cells release, loading them with signals linked to blood-vessel growth and healing. In some studies the number of particles did not rise. None of this has been tested in patients, so it is an idea about how shockwave might work, not proof that it helps.
Do shock waves change the release and cargo of extracellular vesicles, and could these vesicles carry part of the tissue-repair effects attributed to shock-wave treatment?
Narrative review with a PRISMA-guided search of four databases (to 10 June 2026) and blinded screening by two researchers: 6 core cell and animal studies of shock-wave-induced extracellular vesicles, plus background literature. Quality screening relied on vesicle-characterization standards; no formal risk-of-bias tool, no pooled estimate and no human study of the shock-wave–vesicle link.
Cell and animal work only: human umbilical vein endothelial cells, endothelial colony-forming cells, H9c2 cardiomyoblast-like cells, bone-marrow mesenchymal stem cells and adipose-derived stromal cells; a mouse myocardial infarction model, a rat skin-wound model with tibial osteotomy and a rat model of diabetic bladder dysfunction. The human studies cited concern circulating microRNAs in heart and vascular disease, not shockwave treatment.
No treatment was given by the authors. Core studies used 0.09–0.12 mJ/mm² with 500 shots, 0.1 mJ/mm² with 800 impulses, or 3 bar with 300 impulses at 5 Hz; most treated donor cells in culture and gave their vesicles to animals, and one applied shock waves at a rat tibial osteotomy.
Vesicles from shock-wave-treated versus untreated cells or animals; inhibitor, knockdown and overexpression experiments; tibial osteotomy alone versus osteotomy plus shock wave. No sham-controlled comparison in people.
Vesicle yield and markers (CD63, TSG101, Rab27), signalling (ATP/P2X7R/p38 MAPK, nSMase2), vesicle microRNA and protein cargo, endothelial tube formation, cell survival after oxygen deprivation, wound closure, heart function and fibrosis in mice, and bladder voiding, capillary density and nerve fibres in rats.
Among the five studies in Table 3, vesicle yield rose in two, did not rise in two and was not measured in one. Vesicles from treated cells carried altered cargo (the microRNAs miR-19a-3p, miR-140-3p and miR-98-5p; the proteins Thbs1, Lcp1 and Hspd1; the transcription factor GATA4) linked in the laboratory to vessel growth, cell survival and a shift of macrophages to the M2 type. In mice, injected vesicles from treated endothelial cells preserved heart function after infarction; in rats, shock wave at a tibial osteotomy improved distant skin wounds, an effect weakened by blocking vesicle release. The authors call the shock-wave–vesicle axis a hypothesis that still needs validation.
The review gives no adverse-event data from its core studies, all of which were preclinical. The review notes that excessive mechanical load can injure cells, damage microvessels or worsen inflammation, that vesicle increases must be separated from membrane injury and release of apoptotic debris, and it cites raised inflammatory markers in brain-derived vesicles of military personnel exposed to repeated low-level blasts as a reason to define a safe treatment window. Funding: Liaoning “Xingliao Talent Plan” and Dalian Association of Science and Technology; no conflicts declared and no device-maker ties stated.
The authors note that the evidence is mainly in vitro and small-animal proof of concept, with varied parameters, donor cells, isolation methods and timing, and that their release model is a working hypothesis; heart and bladder models test vesicle products, not release in treated tissue, and GW4869 is not fully specific. The core set is small (6 studies, with 5 in Table 3), has no formal risk-of-bias assessment, and splits on whether vesicle numbers rise.
Background for researchers on one candidate pathway. It cannot estimate benefit, guide dose or show that vesicles mediate any effect of shockwave treatment in people.
Trace vesicle release in treated tissue after defined, clinically used exposures, characterize vesicles to current standards, test causality with specific inhibitors and sham controls in animals, and then measure vesicle changes alongside blinded outcomes in patients.
Read the original article.
From physical impact to biological information flow: shock wave regulation of extracellular vesicles mediated tissue repair
Zhang S, Gao Y, Zhou J, Li T, Liu J, Yang L, Qiao Q, Gong X, Liu Y. · Frontiers in cell and developmental biology · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →